LONDON - Cambridge Antibody Technology plc had a cheery start to the New Year with news that partner Abbott Laboratories Inc. received FDA approval earlier than anticipated to market Humira for rheumatoid arthritis, and the drug will begin shipping this month. (BioWorld International)
